Analyst firms · Raymond James · ADMA
Raymond James ADMA price target and rating history
ADMA Biologics Inc (ADMA) · Health Care
Raymond James rates ADMA Biologics Inc (ADMA) Outperform with a $21 price target, as of its latest action on Jun 10, 2026. It has published 4 rating actions on ADMA since October 2021, including 1 upgrade and 0 downgrades.
- Current rating
- Outperform
- Price target
- $21
- Median target, all firms
- Too few
- Actions on ADMA
- 4
Raymond James price target on ADMA
Every Raymond James rating on ADMA
- Jun 10, 2026
- Jul 19, 2023
- Nov 11, 2021
- Oct 26, 2021
How other firms rate ADMA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Raymond James | Outperform | $21 | Jun 10, 2026 |
| Canaccord Genuity | Buy | $21 | Apr 21, 2026 |
| Cantor Fitzgerald | Neutral | Mar 26, 2026 |
Questions about Raymond James and ADMA
- What is Raymond James's price target for ADMA?
- Raymond James's latest stated price target for ADMA Biologics Inc (ADMA) is $21, from its action on Jun 10, 2026.
- What is Raymond James's rating on ADMA?
- Raymond James rates ADMA Outperform, a bullish rating, as of Jun 10, 2026.
- When did Raymond James last change its view on ADMA?
- On Jun 10, 2026, Raymond James resumes coverage at Outperform, price target $21.
All Raymond James ratingsADMA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.